A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing

Fadi Saade; Y. Honda-Okubo; Samay Trec; Nikolai Petrovsky

doi:10.1016/j.vaccine.2012.12.077

A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing

Fadi Saade, Y. Honda-Okubo, Samay Trec, Nikolai Petrovsky

Research output: Contribution to journal › Article › peer-review

141 Citations (Scopus)

Abstract

Although current HBV vaccines have an outstanding record of safety and efficacy, reduced immunogenicity is a problem in those of older age, or having renal impairment or diabetes mellitus. In this study, we tested the ability of Advax™ adjuvant, a novel polysaccharide adjuvant based on delta inulin, to enhance the immunogenicity of hepatitis B surface antigen (HBs) in mice and guinea pigs by comparison to the traditional alum adjuvant. Advax™ provided antigen-sparing, significantly enhanced both anti-HBs antibody titers, and anti-HBs CD4 and CD8 T-cells, with increases in Th1, Th2 and Th17 cytokine responses. Unlike alum, the adjuvant effect of Advax™ was seen even when injected 24. h before the HBs antigen. Advax™ adjuvant similarly enhanced humoral and cellular immune responses in guinea pigs to a third generation preS-HBs antigen. Advax™ adjuvant when combined with HBs antigen could provide enhanced protection over current generation HBV vaccines for immunization of low responder populations.

Original language	English
Pages (from-to)	1999-2007
Number of pages	9
Journal	Vaccine
Volume	31
Issue number	15
DOIs	https://doi.org/10.1016/j.vaccine.2012.12.077
Publication status	Published - 8 Apr 2013

Keywords

Adjuvant
Advax™
Alum, Therapeutic
Hepatitis B
Inulin
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2012.12.077

Cite this

@article{72966343e4cf4ffca06f324d8945fdb7,

title = "A novel hepatitis B vaccine containing Advax{\texttrademark}, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing",

abstract = "Although current HBV vaccines have an outstanding record of safety and efficacy, reduced immunogenicity is a problem in those of older age, or having renal impairment or diabetes mellitus. In this study, we tested the ability of Advax{\texttrademark} adjuvant, a novel polysaccharide adjuvant based on delta inulin, to enhance the immunogenicity of hepatitis B surface antigen (HBs) in mice and guinea pigs by comparison to the traditional alum adjuvant. Advax{\texttrademark} provided antigen-sparing, significantly enhanced both anti-HBs antibody titers, and anti-HBs CD4 and CD8 T-cells, with increases in Th1, Th2 and Th17 cytokine responses. Unlike alum, the adjuvant effect of Advax{\texttrademark} was seen even when injected 24. h before the HBs antigen. Advax{\texttrademark} adjuvant similarly enhanced humoral and cellular immune responses in guinea pigs to a third generation preS-HBs antigen. Advax{\texttrademark} adjuvant when combined with HBs antigen could provide enhanced protection over current generation HBV vaccines for immunization of low responder populations.",

keywords = "Adjuvant, Advax{\texttrademark}, Alum, Therapeutic, Hepatitis B, Inulin, Vaccine",

author = "Fadi Saade and Y. Honda-Okubo and Samay Trec and Nikolai Petrovsky",

year = "2013",

month = apr,

day = "8",

doi = "10.1016/j.vaccine.2012.12.077",

language = "English",

volume = "31",

pages = "1999--2007",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "15",

}

A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. / Saade, Fadi; Honda-Okubo, Y.; Trec, Samay et al.
In: Vaccine, Vol. 31, No. 15, 08.04.2013, p. 1999-2007.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing

AU - Saade, Fadi

AU - Honda-Okubo, Y.

AU - Trec, Samay

AU - Petrovsky, Nikolai

PY - 2013/4/8

Y1 - 2013/4/8

N2 - Although current HBV vaccines have an outstanding record of safety and efficacy, reduced immunogenicity is a problem in those of older age, or having renal impairment or diabetes mellitus. In this study, we tested the ability of Advax™ adjuvant, a novel polysaccharide adjuvant based on delta inulin, to enhance the immunogenicity of hepatitis B surface antigen (HBs) in mice and guinea pigs by comparison to the traditional alum adjuvant. Advax™ provided antigen-sparing, significantly enhanced both anti-HBs antibody titers, and anti-HBs CD4 and CD8 T-cells, with increases in Th1, Th2 and Th17 cytokine responses. Unlike alum, the adjuvant effect of Advax™ was seen even when injected 24. h before the HBs antigen. Advax™ adjuvant similarly enhanced humoral and cellular immune responses in guinea pigs to a third generation preS-HBs antigen. Advax™ adjuvant when combined with HBs antigen could provide enhanced protection over current generation HBV vaccines for immunization of low responder populations.

AB - Although current HBV vaccines have an outstanding record of safety and efficacy, reduced immunogenicity is a problem in those of older age, or having renal impairment or diabetes mellitus. In this study, we tested the ability of Advax™ adjuvant, a novel polysaccharide adjuvant based on delta inulin, to enhance the immunogenicity of hepatitis B surface antigen (HBs) in mice and guinea pigs by comparison to the traditional alum adjuvant. Advax™ provided antigen-sparing, significantly enhanced both anti-HBs antibody titers, and anti-HBs CD4 and CD8 T-cells, with increases in Th1, Th2 and Th17 cytokine responses. Unlike alum, the adjuvant effect of Advax™ was seen even when injected 24. h before the HBs antigen. Advax™ adjuvant similarly enhanced humoral and cellular immune responses in guinea pigs to a third generation preS-HBs antigen. Advax™ adjuvant when combined with HBs antigen could provide enhanced protection over current generation HBV vaccines for immunization of low responder populations.

KW - Adjuvant

KW - Advax™

KW - Alum, Therapeutic

KW - Hepatitis B

KW - Inulin

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84875257910&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.12.077

DO - 10.1016/j.vaccine.2012.12.077

M3 - Article

SN - 0264-410X

VL - 31

SP - 1999

EP - 2007

JO - Vaccine

JF - Vaccine

IS - 15

ER -

A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this